News and reporting on cell-free DNA testing.
Biocept Prices $5M Public Offering
The San Diego-based company plans to use the proceeds to advance its cerebral spinal fluid liquid biopsy assay, as well as to boost its working capital.
Convergent Genomics Building Data on Urine-Based Assay to Diagnose, Monitor Urothelial Carcinoma
The Oregon Health and Science University spinout also recently presented data suggesting the test could help predict future urothelial carcinoma.
Guardant Health Secures New Commercial Payor Coverage for Liquid Biopsy Cancer Profiling Test
With new coverage from Anthem Blue Cross and Blue Shield, Aetna, and Humana, the firm's Guardant360/Guardant360 CDx assay is now covered by all major commercial health insurers.
Personalis, Ono Pharmaceutical, Japan National Cancer Center Partner on Opdivo Rectal Cancer Trial
In the multicenter VOLTAGE-2 trial, investigators will compare results of the company's tests with standard-of-care measures of drug response.
Jury Awards Natera $19.4M in Damages in Invitae, ArcherDx Patent Infringement Suit
A jury determined that Invitae and ArcherDx have infringed three patents and awarded Natera damages for lost profits and past royalties.